Total amount raised
$448.1 Millions
Latest funding date
1/1/2025
Location
Colossal Biosciences has successfully raised significant funding through multiple rounds, including a Series C, to support its ambitious de-extinction projects.
Keep reading to explore the intricacies of Colossal Biosciences' fundraising journey and the investors backing this innovative company.
What Is Colossal Biosciences?
Colossal Biosciences, founded on February 4, 2021, is a biotechnology and genetic engineering company based in Austin, Texas. The company focuses on de-extincting species using advanced gene editing technologies like CRISPR.
Founded by Andrew Busey, Ben Lamm, Brian Beard, George Church, Kent Wakeford, and Peter Phillips, Colossal aims to revive extinct species such as the woolly mammoth and enhance ecosystems. Their mission addresses challenges related to extinction and biodiversity loss.
With a team of 101-250 employees, Colossal combines the science of genetics with the business of discovery to bring back species like the Woolly Mammoth, Thylacine, and Dodo, aiming to restore ecological balance and advance biological economies.
How Much Funding Has Colossal Biosciences Raised?
- Seed Round
- Amount Raised: $15M
- Date: May 2021
- Lead Investors: Thomas Tull
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's ambitious de-extinction projects and establish initial research and development operations.
- Series A
- Amount Raised: $60M
- Date: March 2022
- Lead Investors: At One Ventures, Thomas Tull
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the team and accelerate the development of genetic engineering technologies.
- Grant
- Amount Raised: Not publicly disclosed
- Date: October 2022
- Lead Investors: IQT
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support specific research initiatives and technological advancements.
- Series B
- Amount Raised: $162.6M
- Date: January 2023
- Lead Investors: US Innovative Technology Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and further develop de-extinction technologies.
- Venture Round
- Amount Raised: $10.5M
- Date: November 2023
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund ongoing research and development efforts.
- Series C
- Amount Raised: $200M
- Date: January 2025
- Lead Investors: Mark Walter, Thomas Tull, TWG Global
- Valuation at Round: $10.2B
- Motivation Behind the Round: To advance genetic engineering technologies and expand the de-extinction species list.
Total Amount Raised: $448.1M. Current Valuation: $10.2B.
Key Investors
- TWG Global
- Details: TWG Global is a diversified holding company led by Mark Walter and Thomas Tull. It has a broad investment portfolio across various sectors.
- Investment Focus Areas: Technology/AI, financial services, private lending, sports, media.
- Notable Investments: Not publicly disclosed.
- US Innovative Technology Fund (USIT)
- Details: USIT is a venture capital firm that invests in innovative technology companies. It aims to support groundbreaking advancements in various fields.
- Investment Focus Areas: Technology, biotechnology, innovation.
- Notable Investments: Not publicly disclosed.
- At One Ventures
- Details: At One Ventures is a venture capital firm focused on backing companies that are working towards a sustainable future. It was founded by Tom Chi, a former Google X co-founder.
- Investment Focus Areas: Sustainability, technology, environmental innovation.
- Notable Investments: Not publicly disclosed.
- In-Q-Tel (IQT)
- Details: In-Q-Tel is a non-profit strategic investor that supports the U.S. intelligence community by investing in cutting-edge technology companies. It was founded in 1999.
- Investment Focus Areas: Security, data analytics, biotechnology.
- Notable Investments: Palantir Technologies, FireEye, Keyhole (acquired by Google).
- Breyer Capital
- Details: Breyer Capital is a global venture capital and private equity firm founded by Jim Breyer. It focuses on long-term investments in groundbreaking companies.
- Investment Focus Areas: Technology, media, healthcare.
- Notable Investments: Facebook, Etsy, Marvel Entertainment.
What's Next for Colossal Biosciences?
Colossal Biosciences stands at the forefront of genetic engineering, with opportunities spanning de-extinction, species preservation, and human healthcare. The company’s recent $200 million Series C funding will fuel advancements in software, wetware, and hardware solutions, positioning it to tackle the biodiversity crisis and beyond.
Future fundraising appears promising, given the strong backing from high-profile investors and the company's ambitious goals. However, Colossal faces challenges such as ethical concerns, regulatory hurdles, and the technical complexities of de-extinction. Navigating these obstacles will be crucial for sustained growth and innovation.
Use Clay to Get Funding Data
Sales professionals, take your prospecting to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Colossal Biosciences and gather other critical business insights.
Sign up for free on Clay and start transforming your sales strategy today.
